Plasuo-Phi Injection

Adult administration

Typically, 500 to 1,000 mL is administered by slow intravenous infusion to adults. The administration rate is 200 mL per hour. The dosage and rate of administration should be adjusted appropriately according to age, weight, and symptoms.

This medication may cause allergic reactions during use, so if there are signs of hypersensitivity, administration should be discontinued immediately, and appropriate treatment must be sought. As it contains a high amount of potassium, there is a risk of hyperkalemia, so patients with impaired renal function, heart disease, or those taking medications that may raise potassium levels should exercise caution. High sodium and chloride concentrations may lead to electrolyte imbalances such as hypernatremia, hyperchloremic acidosis, and metabolic acidosis. Patients with hypertension, liver disease, or heart failure should be carefully monitored for fluid overload or edema while using this medication. This drug may cause hyponatremia, so special caution is required for children, elderly patients, postoperative patients, and those taking medications that may cause low sodium levels. If symptoms such as headache, vomiting, seizures, or drowsiness occur, it is essential to inform medical personnel immediately, and regular monitoring of serum sodium levels and neurological status should be conducted. Due to the risk of fluid overload, the infusion amount and speed should be adjusted, and fluid balance and electrolyte status should be continuously monitored during prolonged administration. This medication should not be administered to patients with hypervolemia, hypernatremia, or those who have had hypersensitivity reactions to this drug. Careful administration is required in patients with heart failure, renal failure, hyperkalemia, metabolic alkalosis, and impaired liver function, and blood tests and clinical status should be frequently checked if necessary. Local warmth, infection, or thrombosis may occur at the injection site, and rapid administration may cause cerebral edema, pulmonary edema, swelling, and metabolic alkalosis. Since this drug contains sodium, caution is needed when used in conjunction with medications such as corticosteroids that increase sodium retention. The risk increases when used with drugs that cause hyperkalemia, so serum potassium levels must be monitored. Caution is also required when used with lithium, as blood lithium levels may fluctuate. When used with diuretics, anticonvulsants, or psychotropic drugs that pose a risk of hyponatremia, serum sodium levels should be checked frequently.

Serious side effects

Allergic reaction (including anaphylaxis), cardiac arrest, cerebral edema, pulmonary edema, peripheral edema, headache, seizures, fever, severe allergic reaction, fluid overload, severe rash accompanied by high fever, blisters, skin peeling, pain in mucous membranes of mouth/eyes, difficulty breathing or shortness of breath, asthma attack, respiratory abnormalities accompanied by cough and fever, jaundice (yellowing of skin or eyes), severe lethargy, sudden and severe headaches, lightning-type headache

Mild side effects

• Local warmth at the injection site
• infection
• venous thrombosis
• phlebitis
• effusion
• hypervolemia
• systemic papules and erythema
• rash
• vomiting
• hypertension

This medication should be stored in a sealed container to protect it from air and moisture. It is advisable to keep it at room temperature rather than in excessively hot or cold places.

Appearance

A colorless and transparent injection in a polypropylene or multi-layer film plastic container

Package unit

500mL/bag, 1000mL/bag